SalvaRx offloads immuno-oncology assets to Portage Biotech
14th Aug 2018 14:19
(Sharecast News) - AIM-listed biotechnology company SalvaRx has entered into a conditional sale agreement that would see the Cambridgeshire-based firm offload its immuno-oncology assets to Portage Biotech.
Read moreSalvaRx takes chunk of Intensity Therapeutics
22nd Apr 2016 16:42
(ShareCast News) - Cancer-focused biotechnology firm SalvaRx expanded its investment portfolio on Friday, taking a chunk of US-based Intensity Therapeutics - an outfit pioneering a new approach to treating solid tumours. The AIM-traded company confirmed it invested $2m in cash for a 9.2% interest in
Read moreSalvaRx subsidiary part of grant-receiving cancer drug consortium
21st Apr 2016 16:47
(ShareCast News) - SalvaRx announced a potential win for both shareholders and cancer patients on Thursday, with its subsidiary iOx being part of an 11-partner consortium receiving an €8.3m Horizon 2020 grant from the European Commission for a potential new product. The AIM-traded company said iOx w
Read more